In the wake of Medicare’s announcement of the first 10 drugs subject to price negotiations, Patients Rising CEO Terry Wilcox outlines the need for greater patient involvement in this process; Taylor Schwartz of Avalere explains a new white paper...
In the wake of Medicare’s announcement of the first 10 drugs subject to price negotiations, Patients Rising CEO Terry Wilcox outlines the need for greater patient involvement in this process; Taylor Schwartz of Avalere explains a new white paper that analyzes the use of patient-centered outcomes in ICER reviews; CMS issues draft guidance on new Medicare Part D smoothing program.
Patients Rising Calls on CMS to Engage with Patients in Drug Price Negotiations
Patients Rising Now Comments: Medicare Drug Price Negotiation Program Guidance Memo
CMS Webpage: Medicare Drug Price Negotiation Program
Avalere Webpage: Use of Patient-Centered Outcomes in ICER Assessments